The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Start Date01 Sep 2025

Sponsor / Collaborator

NYU Langone Health

NCT06716606

/ RecruitingPhase 3

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

This is an open label extension (OLE) study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

Start Date12 Dec 2024

Sponsor / Collaborator

GSK Plc

[+1]

NCT06381453

/ RecruitingPhase 2IIT

Belimumab in the Management of Autoimmune Hepatitis: a Multi-centre, Open-label Trial of Add-on Belimumab Therapy to Standard of Care

Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression. Current therapies are limited, not targeted, and associated with side effects that patients report reduce quality of life. AIH is believed to arise as a consequence of genetic & environmental risks. Disease is characterised by impaired immunoregulation, that favours a chronic and relapsing hepatitis. As well as recognising an important role for cytotoxic T cells and regulatory T cells, it has become apparent that in AIH, as well as other related autoimmune conditions, that B-cells are important. AIH is characterised by a plasma cell rich interface hepatitis and elevated IgG concentrations. Furthermore B-cell lineages interact with regulatory T-cells. Off-label use of Rituximab, an anti-CD20 agent, has been described for patients with AIH. A number of other ways of effectively targeting B-cells in the treatment of related autoimmune diseases have also been developed, but there have been limited studies in people living with autoimmune hepatitis. Belimumab is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator. It is approved in the Canada to treat systemic lupus erythematosus and lupus nephritis. It has not been studied before in AIH, but off-label reports are published. In an open-label clinical trial of people living with autoimmune hepatitis, the investigator will now formally study the effect of adding Belimumab to existing standard of care, with the goal being to evaluate treatment efficacy, the ability to reduce the burden of existing therapies whilst still controlling AIH disease, and to describe the tolerability & safety of Belimumab in people with AIH. Study Design: Open label, multi-centre, Canadian clinical trial. Patient population: Patients with autoimmune hepatitis, excluding patients with decompensated liver disease, who either have active disease despite standard of care (Group A), or who are maintained with disease remission using standard of care therapy (Group B). 48 patients will be recruited. Intervention: Weekly sub-cutaneous Belimumab. Duration: 72 weeks with interim analysis after 24 patients have been treated for 24 weeks; target recruitment 48 patients. Evaluation: Safety, Serum liver tests, quality of life, exploratory immunologic biomarkers, optional liver biopsy or fine needle liver aspirate. Primary end-point: Group A: 50% or more of subjects have an ALT<2x ULN & corticosteroids at a dose of

Start Date11 Dec 2024

Sponsor / Collaborator

University Health Network

[+1]

100 Clinical Results associated with Belimumab

100 Translational Medicine associated with Belimumab

100 Patents (Medical) associated with Belimumab

1,300

Literatures (Medical) associated with Belimumab

01 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.

Article

Author: Sarocco, Phillip ; Kardel, Peter ; Maynard, Jason ; Sheetz, Caitlin

INTRODUCTION:

Comparisons of subcutaneous (SC) and intravenous (IV) delivery of biotherapeutics in Europe have revealed differences in cost, convenience, and preference. In the US, claims-based studies comparing SC and IV delivery have been limited. This study compared resource utilization and expenditures between cohorts of patients receiving the same drug by the SC or IV route of administration (ROA) across several indications.

METHODS:

Medicare Fee-For-Service claims were compared between cohorts of patients who received SC- or IV-delivered abatacept, belimumab, daratumumab, infliximab, tocilizumab, trastuzumab/pertuzumab, or vedolizumab. For each drug, utilization rates and healthcare expenditures per service site were compared between ROAs. Observed differences in baseline characteristics were accounted for using Inverse Probability Treatment Weighting models that balanced pre-index differences between ROAs per drug. Each ROA comparison per drug and service site was weighted and conducted independently.

RESULTS:

Across seven drugs, a total sample size of 158,632 (72,820 IV; 85,812 SC) was analyzed. For most comparisons, high-spend sites were utilized at a higher rate for IV administration. In particular, all comparisons revealed more frequent hospital outpatient department utilization for the IV ROA. For five of the seven drugs, SC treatment was associated with lower mean total Medicare expenditures, with savings of up to $56,000 per patient annually. Although three SC treatments had higher medication index spend, the total spend for these drugs across sites was significantly lower for SC delivery.

LIMITATIONS:

Limitations of this study include differences in billing between the SC and IV ROAs, potential treatment selection bias, and the assumption of equivalent efficacy.

CONCLUSIONS:

To our knowledge, this study was the first and largest US Medicare claims analysis, comparing patients receiving SC or IV versions of the same therapeutic across multiple drugs and indications. Findings demonstrated that SC delivery may facilitate reduced resource utilization and expenditures across drugs and disease indications.

01 Dec 2025·IMMUNOLOGIC RESEARCH

Effects of belimumab on peripheral blood Breg cells and cytokines in childhood systemic lupus erythematosus

Article

Author: Qiu, Shan ; Peng, Qianqian ; Zhang, Ruifeng ; Chen, Na ; Lu, Qian ; Yuan, Tingting ; Zhong, Zhaowen ; Lv, Juan

To evaluate the therapeutic effectiveness of belimumab (BLM) in childhood systemic lupus erythematosus (cSLE) by analyzing peripheral blood Breg cell subsets and related cytokines at multiple time points post-treatment, compared with conventional therapy. From January 2023 to August 2023, 36 cSLE patients receiving BLM plus standard therapy (BLM group) and 35 receiving standard therapy alone (conventional group) were enrolled. Thirty age- and sex-matched healthy children were included as controls. Flow cytometry was used to detect absolute counts and ratios of peripheral Breg cell subsets at baseline, 6 weeks, 6 months, and 1 year. Serum cytokine levels (IL-2, IL-10, IL-21, IL-35, and IFN-γ) were measured by ELISA. After 6 weeks, IL-2, IL-21, and IFN-γ levels decreased significantly in both groups (P > 0.05 between groups); however, after 6 months and 1 year, these cytokines remained lower in the BLM group (all P < 0.05). IL-10 and IL-35 levels increased in both groups from week 6, with a milder increase in the BLM group (all P < 0.05). CD3⁻CD19⁺ B cells declined in both groups, with significant intergroup differences (P < 0.001). The BLM group showed a higher proportion of CD27⁺CD24⁺ B cells at week 6 compared to the conventional group (P < 0.05), but this reversed at 1 year (P < 0.05). CD38⁺CD24⁺ B cells were significantly higher in the BLM group at 6 months and 1 year (P < 0.001), while the conventional group showed no significant change after 6 weeks (P > 0.05). At baseline, the relative proportion of CD38⁺CD19⁺ B cells was higher in the BLM group than in the conventional treatment group (all P < 0.05). With ongoing treatment, both groups showed a decreasing trend in B cell proportions, with statistically significant differences observed within each group (all P < 0.05). Moreover, the decline in the BLM group was more pronounced compared to the conventional group at corresponding time points (all P < 0.05). Belimumab may exert immunomodulatory effects in childhood systemic lupus erythematosus by influencing peripheral Breg cell subsets and cytokine profiles. Compared with conventional therapy, it appears to provide more sustained regulation of certain immune parameters over time. These findings suggest its potential as a complementary therapeutic option targeting B cell dysregulation in cSLE, although further studies are needed to confirm these observations and clarify the underlying mechanisms.

01 Nov 2025·KIDNEY INTERNATIONAL

Childhood-onset lupus nephritis: unique aspects and challenges in management

Review

Author: Chan, Eugene Yu-Hin ; Marks, Stephen D

Childhood-onset lupus nephritis is an important glomerular disease that requires safe and effective treatments to reduce the incidence of chronic kidney disease and kidney failure. Novel treatments have become available for adults in the last decade, notably belimumab, obinutuzumab, and voclosporin. In contrast, most children with lupus nephritis are treated with conventional immunosuppression, and treatment recommendations are extrapolated from adult data because pediatric patients have historically been rarely included in clinical trials. However, children are not small adults with evolving immune systems, and there is a significant role of genetics contributing to the complex disease pathogenesis. In this mini review, we will highlight several unique aspects in managing childhood-onset lupus nephritis, including the optimal definition of disease remission, prevention of relapse, the delicate balance between treatment efficacy and side effects, and monogenic forms of lupus nephritis. We will also discuss how treatment adherence and dedicated transition care can affect treatment outcomes.

102

News (Medical) associated with Belimumab

20 Oct 2025

·www.fiercepharma.com

Roche's aging oncology blockbuster Gazyva snares FDA nod to move into lupus nephritis

With the lupus nephritis nod, Gazyva could reach sales of $1.7 billion by 2030, analysts at GlobalData have predicted. With the lupus treatment landscape poised for a shake-up, Roche is hitting the scene in the U.S. with a new green light for its long-approved blood cancer medicine Gazyva.Early Monday, Roche’s Genentech announced that the FDA cleared Gazyva (obinutuzumab) to treat adults with active lupus nephritis who are taking standard therapy.The drug will be given as four initial infusions during the first year of treatment, after which it can be administered twice yearly. Lupus nephritis is a potentially fatal manifestation of the most common form of lupus, systemic lupus erythematosus (SLE), which results in the irreversible loss of filtering structures in the kidneys called nephrons. Many patients with lupus nephritis lose kidney function over time, and, even with the most current treatments, up to one-third of people living with the autoimmune disease progress to end-stage kidney disease, according to Roche. Enter Gazyva, a monoclonal antibody drug targeting CD20—a protein found on certain types of B cells—which Roche has surmised could move beyond its blood cancer roots to protect the kidneys of those with lupus nephritis from further damage and slow or prevent kidney disease progression to the severest stage. Lupus nephritis is itself a B cell-driven disease.The FDA signed off on Roche’s thesis as it was borne out in the drugmaker’s late-stage Regency study and phase 2 Nobility trial. In Regency, more than 46% of patients who received Gazyva together with standard therapy hit complete renal response, compared to 33.1% of patients on standard care alone.“People with lupus nephritis who achieve a complete renal response are more likely to experience preserved kidney function and delay, or even prevention, of progression to end-stage kidney disease,” Levi Garraway, M.D., Ph.D., Roche’s chief medical officer and head of global product development, said in a statement.Roche’s med also led to clinically meaningful improvements across complement levels and reductions in anti-double-stranded DNA (anti-dsDNA) antibodies, corticosteroid use and high levels of protein in the urine, which the company spotlighted as signals of improved disease control.“The approval of Gazyva by the FDA marks an important step towards a potential new standard of care for lupus nephritis, one that could allow clinicians to offer their patients more effective disease control,” Garraway continued in Roche’s release.Despite wins on renal response and disease activity metrics, Roche’s drug came up short on secondary responses that tracked patients’ mean change in estimated glomerular filtration rates (eFGR), death or renal-related events and overall renal responses. EGFR is a measure of how well the kidneys are filtering waste and extra water from the blood to make urine.The move into lupus nephritis comes late into the life span of Gazyva, which was initially endorsed by the FDA in chronic lymphocytic leukemia (CLL) back in 2013. The lupus nephritis nod marks the drug’s fifth, following several green lights in additional CLL and follicular lymphoma indications over the years.More than 1.7 million people around the world live with lupus nephritis, Roche said in its release. The condition disproportionately affects women and, among women, even more so women of color and those who are of childbearing age. Patients with lupus nephritis who progress to end-stage kidney disease often require dialysis or transplantation to address their disease.As it stands, the lupus treatment market—across several distinct indications—is dominated by GSK’s biologic Benlysta. The drug, which falls into the B-lymphocyte stimulator (BlyS)-specific inhibitor class—originally passed muster with the FDA in 2011.More recently, AstraZeneca in 2021 scored an FDA nod for its drug Saphnelo to treat moderate to severe SLE. Doctors have also used another Roche drug, Rituxan, off-label to treat lupus nephritis for some time now. Roche had previously tried to secure a lupus nod for the CD20 antibody but failed after Rituxan fell short in a phase 3 trial. Meanwhile, Gazyva has continued to grow sales through its oncology footholds in recent years, delivering 16% growth to 910 million Swiss francs (around $1.15 billion) for all of 2024, according to Roche’s latest annual report (PDF). With the lupus nephritis nod, Gazyva could now reach sales of $1.7 billion by 2030, analysts at GlobalData have predicted. The FDA endorsement comes less than a week after the European Medicine Agency's Committee for Medicinal Products for Human Use issued a similar recommendation for Gazyva, in tandem with mycophenolate mofetil, to treat lupus nephritis. The drug will now go before the European Commission for final regulatory sign-off.

Drug ApprovalPhase 3Phase 2Accelerated Approval

17 Sep 2025

·firstwordpharma.com

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

AstraZeneca reported positive Phase III results Wednesday for a subcutaneous formulation of Saphnelo (anifrolumab), saying the treatment significantly cut disease activity in patients with systemic lupus erythematosus (SLE) and matched the safety seen with the currently approved intravenous (IV) version. Findings from an interim analysis of the TULIP-SC study will be presented next month at the American College of Rheumatology's (ACR) annual meeting.The TULIP-SC trial evaluated subcutaneous administration of Saphnelo against placebo in 367 patients with moderate-to-severe, autoantibody-positive SLE who were receiving standard background therapy consisting of oral corticosteroids, antimalarials, and/or immunosuppressants. The drug was administered once weekly via an accessorised prefilled syringe.Disease activity was measured using the British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA), which requires sustained improvement across all affected organs with no new flares. The interim analysis, based on data from the first 220 participants who reached week 52, showed a statistically significant and clinically meaningful benefit over placebo, according to AstraZeneca.Under regulatory review"Despite guidelines recommending earlier intervention and biologic treatments, too many people with systemic lupus erythematosus rely on oral corticosteroids, which contribute to irreversible organ damage," commented Susan Manzi, principal investigator for the study. "Today's results… provide the opportunity for this important biologic to reach a wider group of patients in a more flexible and convenient way."AstraZeneca noted that the TULIP-SC data are now under regulatory review. Sharon Barr, head of BioPharmaceuticals R&D at the drugmaker, said the results "are especially important because approximately half of systemic lupus erythematosus patients today taking a biologic are already treated with a self-administered subcutaneous option."Saphnelo was originally cleared in 2021 for administration by IV infusion in adults with moderate-to-severe SLE receiving standard therapy. If approved, the subcutaneous form would compete more directly with GSK's Benlysta (belimumab), which gained separate US and European nods in 2017 for its self-injectable version based on the BLISS-SC study, where 60.8% of patients achieved a response on the SLE Responder Index (SRI) after 52 weeks, versus 48.5% on placebo.

Clinical ResultPhase 3

09 Sep 2025

·www.biospace.com

Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline

Pictured: Biogen’s signage at its headquarters in Massachusetts iStock, JHVEPhoto With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.” With its storied multiple sclerosis franchise under increasing pressure from declining sales, Biogen’s other programs are stepping into the spotlight—including one where the biotech is leveraging that deep well of immunological experience. Last week, the Cambridge, Mass.–based company held an investor call highlighting its lupus portfolio, helmed by two late-stage assets representing a multi-faceted approach to the autoimmune disease. The first of these, dapirolizumab pegol, being developed in collaboration with UCB, is currently in a second Phase III study with confirmatory data expected in late 2027 or 2028. Meanwhile, litifilimab is involved in three ongoing Phase III studies, all reading out in the next couple of years. “We’re at this inflection point now,” Diana Gallagher, senior vice president of the Multiple Sclerosis and Immunology Disease Unit and Alzheimer’s and Dementia Disease Unit at Biogen, told BioSpace prior to the investor presentation. “We’ve been working in lupus for almost the whole decade that I’ve been here, but really are now at this really exciting point.” Diana Gallagher When asked if the lupus franchise is taking the place of MS in terms of clinical development, Gallagher said, “hopefully it’s a ‘yes, and’ kind of answer. “I still have this sort of really interesting MS portfolio,” she continued. “But yes, I do think that there is intention at Biogen to have this exciting neurology pipeline, an immunology pipeline and a rare disease pipeline. You’ll see the three really pillars of our strategy.” At least one analyst firm reacted positively to the peek under Biogen’s immunological hood. “Biogen lupus pipeline event highlights thoughtful approach to develop assets targeting a diease [sic] with high unmet need,” BMO Capital Markets wrote Sept. 3 in a note to investors. Zooming out on the company, the group added, “With commercial stories like Leqembi, Skyclarys, and Spinraza taking more priority, we are starting to get the feeling that Biogen’s pipeline may be underappreciated, a point emphasized by today’s presentation.” The Lupus Landscape A complex autoimmune disease affecting multiple organ systems and disproportionately afflicting women and people of color, lupus has long proven difficult to treat. In the past 50 years, there have only been two drugs approved for lupus, Gallagher said: GSK’s Belimumab, approved in 2011, and AstraZeneca’s Saphnelo , greenlit in 2021. “So it’s really been quite quiet.” In terms of barriers to therapeutic progress, Gallagher pointed to potential sociodemographic reasons and a complicated biology. “People felt like they couldn’t unravel it. They’re like, oh, there’s so much redundancy, we don’t know what targets to go after.” Adding to these challenges, she said, have been “a lot of failed trials, which makes people shy away, because they’re like, oh, nothing works.” However, she said, the space is “definitely making great strides.” Biogen’s Approach While tackling lupus is a tall order, Gallagher said Biogen “feel[s] like we understand the complexity of immunology and having to have a multi-faceted approach.” And while lupus and MS are certainly not the same, Gallagher pointed to several similarities. Both diseases are immunologically based, predominantly affect young women— approximately 90% of lupus diagnoses are in female patients—and have a relapsing/remitting course. Biogen was one of the first companies “to go into MS and uncouple all that and bring multiple drugs to market,” Gallagher said. “We see [lupus] as another sort of area that we can spend that time that it takes—and we’ve been at it for a couple decades now—to really unravel this and bring a multi-faceted approach for these patients who really have been waiting a long time to have adequate therapy.” As for this multi-faceted approach, dapirolizumab pegol (DZP), a humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding fragment, is targeting SLE. DZP inhibits the signaling of CD40L, a key target to disrupt CD40 signaling and interrupt the immunological cascade in SLE, according to Biogen’s investor presentation on Wednesday. Biogen and UCB claimed a Phase III win for DZP last September in what Stifel analysts at the time called a “positive surprise.” This followed a Phase II failure for the drug in 2018 when it was unable to demonstrate a significant dose response at 24 weeks. Despite the missed endpoint, the partners pushed forward, betting on what they flagged as “consistent and potentially meaningful improvements” across “majority of clinical endpoints.” So far, this bet appears to have paid off. A second Phase III candidate, litifilimab, a humanized IgG1 monoclonal antibody targeting BDCA2, is in development for both SLE and cutaneous lupus erythematosus (CLE). The BDCA2 receptor is predominantly expressed on a subset of immune cells called plasmacytoid dendritic cells (pDCs). When binding to BDCA2, litifilimab has demonstrated the ability to reduce production of pro-inflammatory molecules by pDCs, including type-I interferon, cytokines and chemokines, pro-inflammatory mediators that are thought to play a significant role in both SLE and CLE, according to Biogen . The first Phase III data for litifilimab, from two trials in SLE, are expected by the end of 2026, Gallagher said, while Phase III CLE data should follow in 2027. Finally, Biogen’s 2024 acquisition of Human Immunology Biosciences (HI-Bio) brought into the fold felzartamab, an investigational antibody targeting CD38. Biogen is studying felzartamab in a range of disease areas, including lupus nephritis, where it’s currently in a Phase Ib trial. Gallagher hopes to see topline data from this trial next year. “So next year, for sure, a lot of cards flipping,” she said. “It’s exciting.”

Phase 3ImmunotherapyDrug ApprovalAcquisitionPhase 2

100 Deals associated with Belimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D03068	Belimumab	L04AA26	DB08879

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lupus Nephritis	European Union	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Iceland	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Norway	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Systemic Lupus Erythematosus	United States	GlaxoSmithKline LLC	09 Mar 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchial Diseases	Phase 3	China	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	Japan	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	Argentina	GSK Plc	12 Dec 2024
Bronchial Diseases	Phase 3	South Korea	GSK Plc	12 Dec 2024
Connective Tissue Diseases	Phase 3	United States	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	China	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Japan	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Argentina	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Australia	GSK Plc	11 Sep 2024
Connective Tissue Diseases	Phase 3	Belgium	GSK Plc	11 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04908865 (GSK Study 213560, CTgov)	Phase 4	Systemic Lupus Erythematosus	67	Belimumab	zsdwehaxbs = hdmrklcjow gampyfinnh (znhtmuleqx, zkirceudll - vchtwdcwyn) View more	-	23 Jul 2025
EULAR2025	Not Applicable	Thrombocytopenia \| Lymphopenia	112	Belimumab (Thrombocytopenia)	hzvjvhvpcg(vsfpcffota) = bzhvttjscj nsegrtiocw (zfpncsamdr, 5.5) View more	Positive	11 Jun 2025
EULAR2025	Not Applicable	Systemic Lupus Erythematosus	45	Belimumab	xbliurhnot(kgudwprzcp) = bexmztpzim upzoldrbkl (ieunkirdli )	Positive	11 Jun 2025
				Anifrolumab	yqdnbnlulz(rdreyqrfnm) = gjfuuwsdug tvlhogmsll (fbjcmpmphs )
NCT04908865 (GSK Study 213560, EULAR2025)	Phase 4	Systemic Lupus Erythematosus	67	Belimumab 10 mg/kg IV (plus ST)	cwamjkzzef(smyqsajzbc) = sbyluxyoyx hjcmhyrhvf (ubdhdqgbrh ) View more	Positive	11 Jun 2025
BLISS-52 and BLISS-76 (Pubmed \| Rheumatol Adv Pract)	Phase 3	Systemic Lupus Erythematosus	1,642	Belimumab	dqnmejklks(iffcwybfxv) = lolckzndke hfhbojsxii (ljglaupnrr )	-	14 Mar 2025
				Placebo	dqnmejklks(iffcwybfxv) = cdfzjlixny hfhbojsxii (ljglaupnrr )
ACR2024	Not Applicable	Systemic Lupus Erythematosus	195	Belimumab	zfcfflexfw(ueddplloph) = xburzqmcoa xxxebmzcdh (rwyozpgixl ) View more	Similar	10 Nov 2024
				Telitacicept	zfcfflexfw(ueddplloph) = gbuikqhnor xxxebmzcdh (rwyozpgixl ) View more
NCT00424476 (BLISS-52, ACR2024)	Phase 3	Systemic Lupus Erythematosus	2,370	Belimumab	aoweiiwexg(fklhtkkhrh) = xekammbwcf zhgotlqoqr (jrworjnddm )	Positive	10 Nov 2024
				Placebo	aoweiiwexg(fklhtkkhrh) = xbpjuvibpd zhgotlqoqr (jrworjnddm )
Study 217537 (ACR2024)	Not Applicable	Systemic Lupus Erythematosus	4,750	Belimumab	hcmkqzngik(qrcmlxwbtg) = vxthwqaznq gjmhaesqie (pmenpulujv )	Positive	10 Nov 2024
				prior immunosuppressant use	hcmkqzngik(qrcmlxwbtg) = lbfitqfqhj gjmhaesqie (pmenpulujv )
ACR2024	Not Applicable	Lung Diseases, Interstitial	23	Belimumab+Tocilizumab	resuymmxap(nekiqugdux) = uqktkvgzbt ioeoopwurb (xyfdeipufb ) View more	Positive	10 Nov 2024
ACR2024	Phase 3	Systemic Lupus Erythematosus	3,086	Belimumab+Standard Therapy	lfbxxdvbme(vwhqkuisah): HR = 0.72, P-Value = < 0.0001 View more	Positive	10 Nov 2024
				Placebo+Standard Therapy

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis